Autopsy report · NCT06268574

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 7 months before it stopped.
62 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Ryvu Therapeutics SA
Sponsor type: Industry
Conditions: Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome
Interventions: RVU120
Participants: 62
Sites: 41
Countries: France, Italy, Poland, Spain

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.